Mastic and Reduced miR-155 Level

• Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action.

  • 2021-09
  • RCT
  • Pharmacological research 171
  • • Charalampia Amerikanou
    • Efstathia Papada
    • Aristea Gioxari
    • Ilias Smyrnioudis
    • Stamatia-Angeliki Kleftaki
    • Evdokia Valsamidou
    • Victoria Bruns
    • Rajarshi Banerjee
    • Maria Giovanna Trivella
    • Natasa Milic
    • Milica Medić-Stojanoska
    • Amalia Gastaldelli
    • Aimo Kannt
    • George V Dedoussis
    • Andriana C Kaliora

  • PubMed: 34224858
  • DOI: 10.1016/j.phrs.2021.105753

  2 Insights on

  • Reduced miR-155 Level

  • High evidence
  • Clinical

  In IBD and particularly in ulcerative colitis patients in relapse, miR-155 increased in the placebo group (p = 0.054) whereas this increase was prevented by Mastiha. The mean changes were different in the two groups even after adjusting for age, sex and BMI (p = 0.024 for IBD and p = 0.042).

  Effect

  Beneficial

  Effect size

  Small

  Significant

  Yes